Genmab A/S and GlaxoSmithKline (GSK) announced the approval of Arzerra (ofatumumab) by the Japanese Ministry of Health, Labor and Welfare (MHLW) for use in patients with relapsed / refractory CD20-positive chronic lymphocytic leukemia (CLL). The approval triggers a milestone payment of DKK 20 million from GSK to Genmab.
"We are pleased that patients in Japan will now have access to Arzerra. Japan is another important market for Arzerra and commercialization continues on track," said Jan van de Winkel, Ph.D. Chief Executive Officer of Genmab.
CAR T was just approved for Relapsed/Refractory CLL/SLL ( Potentially 20% CURE rate)
FDA APPROVAL FOR ZANUBRUTINIB
Approval of Imbruvica Frontline for 17p deleted CLL and Important Trials
Israel approves third dose for immunocompromised
Australians have your say in getting CLL medicines approved
